Yesterday BDZ wrote:

However, also possible that there is no advanced top-line announcement and the ESC late breaker serves as the grand reveal of the primary outcome was met, as well as reveal of the details such as %RRR, etc.

The April 18 PR stated that:

Approximately two weeks after DBL, the primary endpoint and additional secondary and exploratory endpoints are expected to be announced.

I fully recognize that BDZ is just covering all the bases (as he does) and is simply tossing this out as a possibility and nothing more.  While the above statement in the PR does not directly imply that there may not be an advanced topline announcement, it does tend to lean more toward a plan to issue topline results when available.  It would, I think, be awfully difficult for the company to sit on this information (for what might be several weeks) until the ESC conference.  But yes, its possible.

While reading the rest of the PR again, I recalled Cabel’s post on April 18 about reading between the lines.  I replied to that post saying that ‘it is cleverly stated to be both positive yet benign at the same time. but  I don’t think you can really draw any conclusions from it. 

I stand by my above comment, however in reading the PR again it does seem to go out of its way to project confidence in the result.  Just for kicks let’s break it down a bit.

the Company’s event-based, phase 3 registration trial has successfully reached 250 projected major adverse cardiac events (MACE),.  Nothing to really read from this other than what it is, 250 MACE without, presumably, any safety or financial issues to hold things up.

Successful data from this trial would enable Resverlogix to proceed towards the regulatory approval and commercialization of its lead drug, apabetalone.  Again, nothing here because if we turn it around it would mean that unsuccessful data would presumably do the opposite.

“Resverlogix staff and stakeholders have worked diligently for the past 18 years to attain this extremely exciting goal,”  I take this to mean that we believe in the science, worked our butts off, spent a pile of money to get here and now we want to cash in…….

“The trial’s extensive breakthrough clinical data will soon be available to Resverlogix.  What is noteworthy here is the added use of the noun ‘breakthrough’.  He could have just said ‘extensive clinical data’, but he went a step further and said ‘breakthrough’.  The word ‘breakthrough is defined as a sudden, dramatic, and important discovery or development; or, an instance of achieving success in a particular sphere or activity.  If the trial fails to achieve its desired endpoint(s) then having used the word breakthrough falls completely flat.  So, by using that word DM is either rolling the dice (unlikely) or displaying a high degree of confidence…..IMO.

Successfully meeting the trial’s endpoints, the substantial data set and otherwise new findings would enable the Company to further solidify its apabetalone program as the world leader in epigenetic BET protein inhibition.  The language here is decidedly positive.  There is no ‘if’ or ‘should’ or other ambiguous word usage here.  Even use of the word ‘would’ isn’t much of a hedge when used in this context.  He says ‘successfully meeting the trials endpoints’ and then goes on to use the word ‘further’….as if the trial result simply ‘adds on’ to what they already know to be true.

 Resverlogix is well positioned to advance therapies for several multi-factorial diseases with significant unmet need, and confirmation of our epigenetic technology would greatly change both the cost effectiveness and efficacy of future medications.” If the trial is successful in meeting its desired outcome(s) then obviously the company is well positioned to proceed further.  The only possible word worthy of mention here is the word ‘confirmation’.  You could take this to mean that, again, the trial is confirming what they already know or (highly) suspect to be true.

“We are nearing completion of this important, potentially transformative study.  This from Dr. Sweeney who couches his statement with the word ‘potentially’.  Nothing else there, as is the case with the rest of his statement .

I’m sure that many of us here have spent time wordsmithing letters and other correspondences.  There is no question that in drafting the April 18 PR, as with other PRs, every word is carefully considered and measured for how it might be interpreted before being sent out.  So, in general, if you think the company is confident in the outcome of this trial, then you may well take the above to heart.  If you add in other intangibles such as, for example, that post by Tundup last June, HL’s continued financing of the trial, the evident absence of wholesale selling of shares after the April 18 announcement, etc. etc. then all of these things point toward a reasonably high degree of optimism in the final outcome.

That said, one thing for sure is that we won’t know for sure until we know for sure.

Sorry for the long post.